Summit Therapeutics Stock Climbs Wednesday: What's Happening?
Shares of Summit Therapeutics moved higher in Wednesday afternoon trading, extending gains from the previous session following a landmark $2.0 billion strategic equity investment from pharmaceutical titan AstraZeneca PLC to accelerate the clinical development of ivonescimab.
A big drug company called AstraZeneca gave Summit Therapeutics two billion dollars. This money helps Summit test and develop a new medicine faster.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.